outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long
unresolved questions about the optimal use of trastuzumab (such as its role in small tumors
or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only
relatively recently. Moreover, with the availability of new highly effective HER2-directed
therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment …
E Lim, EP Winer - 2011 - q4live.s22.clientfiles.s3.amazonaws …
Overview: There has been substantial progress in the man-agement of human epidermal
growth factor receptor 2 (HER2)–positive breast cancer during the last 15 years.
Trastuzumab chemotherapy combinations now form the cornerstone of therapy in both
adjuvant and metastatic disease and are increasingly used in the preoperative setting. As a
result, the natural history of these tumors has been dramatically altered and their prognosis
with anti-HER2 therapy has improved relative to HER2-negative tumors in general. There …